DeepMind and MIT Develop RNA Therapy Against Amyotrophic Lateral Sclerosis

Boston Children's Hospital and MIT have launched a joint research effort into a new approach to treating ALS, amyotrophic lateral sclerosis. With DeepMind's support, the team has combined the biological methods of both laboratories to develop RNA-based therapy for this fatal neurodegenerative disease.

Amyotrophic Lateral Sclerosis: A Challenge for Medicine

Amyotrophic lateral sclerosis (ALS) is a rare but rapidly progressive disease that destroys motor neurons controlling the muscles. Patients gradually lose the ability to walk, speak, swallow, and breathe. The average lifespan after diagnosis is 2-5 years.

Currently, there is no cure capable of stopping or reversing the disease, although several medications slow its progression. There are several types of ALS. About 10% of cases are inherited genetically, when a mutation is passed down from parents.

The remaining 90% are sporadic cases, where the disease's origin remains unclear. This makes drug development particularly challenging: we need to understand numerous mechanisms of nerve cell degeneration and find a way to intervene at the genetic level. Each patient may have their own set of reasons why their motor neurons began to die.

RNA Therapy: A New Tool in Fighting Disease

RNA gene therapy is a relatively young field of biomedicine that allows correcting or suppressing the expression of specific genes within cells. Instead of replacing a defective gene entirely, the RNA approach works more flexibly: it can "switch off" harmful genes or activate protective mechanisms. Researchers from Boston Children's Hospital and MIT decided to combine their methods to create a more effective approach to ALS.

The development of RNA therapy became possible thanks to progress in several areas: we have learned to deliver RNA to nerve cells more efficiently, make more accurate computational predictions about how it will work, and scale the production of new drug candidates. This created a window of opportunity for teams like the one assembled at Boston Children's Hospital and MIT.

The collaboration brings together several key areas:

• RNA interference for selective suppression of mutant genes causing the disease
• Gene delivery of therapeutic molecules to nerve cells in the spinal cord and brain
• Use of computer models and machine learning to predict the efficacy of different approaches
• Preclinical testing on animal models of ALS to assess safety and effectiveness
• Development of optimal dosage, route of administration, and form of drug delivery to the nervous system

DeepMind plays a special role in this effort. The company helps the team analyze large volumes of biological data, identify patterns, and create predictive models. This allows researchers to rapidly navigate through millions of possible treatment variants and focus on the most promising candidates.

The Power of Laboratory Collaboration

Boston Children's Hospital brings deep expertise in gene therapy and two decades of experience working with rare genetic diseases. Clinicians here see ALS patients, understand their needs, and know which drugs have failed before. MIT brings an engineering approach to biology, experience in developing new biotechnologies, and connections with leading biotech companies. Together, these two organizations work at a unique intersection of clinical practice, fundamental biology, computer science, and engineering. Such an interdisciplinary approach is becoming increasingly necessary in fighting diseases that traditional pharmacology and individual laboratories have been unable to overcome. Combining expertise from different centers allows for faster progress from laboratory idea to human clinical trials. History shows: rare diseases require collaboration.

What This Means

This project symbolizes a paradigm shift in the approach to rare neurodegenerative diseases. RNA therapy offers a real chance of creating a cure for ALS, which has long seemed like an unsolvable problem. If the research is successful and passes clinical trials, it could give thousands of patients additional years of life and preservation of functionality. But even more importantly: success with ALS will open doors to developing therapies for other neurodegenerative diseases—Parkinson's disease, ALS-like conditions, and even Alzheimer's disease.